Helicobacter Pylori Infection
Conditions
Keywords
Helicobacter Pylori, quadruple regimen, vonoprazan
Brief summary
The primary objective of this retrospective study was to assess the efficacy and safety of a bismuth quadruple regimen of a low-dose potassium-competitive acid blocker versus a standard-dose potassium-competitive acid blocker and a standard-dose proton pump inhibitor combined with amoxicillin and clarithromycin as the initial treatment of Helicobacter pylori infection.
Detailed description
Helicobacter pylori (H. pylori) infection is closely associated with a variety of diseases including chronic gastritis, peptic ulcer, and gastric cancer. Adequate acid suppression is essential for H. pylori eradication therapy. Potassium-competitive acid blocker (P-CAB) vonoprazan (VPZ) has faster, stronger, and longer-lasting acid inhibition and plays an important role in H. pylori treatment. 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment recommended for the first time a quadruple regimen of bismuth containing P-CAB for H. pylori eradication, in which P-CAB was administered as VPZ 20 mg twice daily. In this retrospective study, we compared the efficacy and safety of a quadruple regimen based on low-dose P-CAB (VPZ 20 mg once daily) versus a quadruple regimen based on standard-dose P-CAB (VPZ 20 mg twice daily) or standard-dose proton pump inhibitor (rabeprazole 10 mg twice daily) containing amoxicillin, clarithromycin, and bismuth as initial treatment for H. pylori infection. Our study will provide clinical evidence for the necessary dosage of VPZ in bismuth quadruple regimens, which will help to further optimize the treatment regimen for H. pylori infection.
Interventions
None listed
Sponsors
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Diagnosis of H. pylori infection confirmed by urea breath test, monoclonal fecal antigen test, endoscopic biopsy histopathology, or bacterial culture; 2. No previous eradication therapy for H. pylori; 3. Age and gender are not restricted.
Exclusion criteria
1. Use of acid-suppressing drugs within 2 weeks prior to treatment, or use of bismuth or antibiotics (including herbal medicines with antimicrobial properties) within 4 weeks prior to treatment; 2. Known hypersensitivity to the drugs used in this study; 3. History of esophageal or gastric surgery; 4. Pregnant or lactating women; 5. Serious systemic diseases, diseases of the heart, lungs, brain and other vital organs, hepatic or renal insufficiency or malignant tumors (except gastric cancer); 6. Patients unable to express their main complaints.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Helicobacter H. pylori eradication rate | after eradication therapy at least 4 weeks | number of patients successfully eradicated / the total number participants |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| safety of regimens | Within 4 weeks from the beginning to the end of therapy | comparison of the incidence of adverse events in each group |
| compliance | 4 weeks after therapy completion | percentage of correctly administered drugs |
Contacts
Primary ContactQin DU
Outcome results
None listed